Nancy A Kernan |
|
|
|
Memorial Sloan-Kettering Cancer Center
·
Department of Pediatrics
|
Publications (129) View all
-
Article: Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.
S Avery, M H Voss, A M Gonzales, M Lubin, H Castro-Malaspina, S Giralt, N A Kernan, A Scaradavou, C V Hedvat, C E Stevens, J N Barker[show abstract] [hide abstract]
ABSTRACT: Delayed or failed engraftment remains a concern after cord blood transplantation (CBT) even when using double-unit grafts. Therefore, we analyzed the association between BM assessment performed approximately 21 days after transplantation, and the speed and success of sustained donor-derived neutrophil engraftment in 56 myeloablative double-unit CBT (DCBT) recipients. Overall, the cumulative incidence of sustained neutrophil engraftment was 95% (95% confidence intervals (CI): 89-100). Of the percentage of myeloid precursors, the BM cellularity and the total donor chimerism the total donor chimerism percentage had the most critical association with the speed and success of engraftment. DCBT recipients who were 100% donor achieved a 98% engraftment rate at a median of 22 days. This compared with 100% engraftment in patients who were 90-99% donor, but at a delayed median of 29 days and only 68% engraftment in patients <90% donor at a median of 37 days (P=0.001). Multivariate analysis was performed in the subgroup of patients who had not engrafted at the time the BM analysis was performed, the subgroup of most clinical concern. This confirmed donor chimerism was predictive of subsequent neutrophil recovery (P=0.004). These findings demonstrate the importance of the day 21 BM chimerism determinations after DCBT.Bone marrow transplantation 12/2011; 47(8):1056-60. · 3.00 Impact Factor -
Article: T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia.
Bone marrow transplantation 07/2011; 47(5):744-6. · 3.00 Impact Factor -
Article: Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
M-A Perales, R Jenq, J D Goldberg, A S Wilton, S S E Lee, H R Castro-Malaspina, K Hsu, E B Papadopoulos, M R M van den Brink, F Boulad, N A Kernan, T N Small, S Wolden, N H Collins, M Chiu, G Heller, R J O'Reilly, T Kewalramani, J W Young, A A Jakubowski[show abstract] [hide abstract]
ABSTRACT: T-cell depleted allogeneic hematopoietic SCT (TCD-HSCT) have shown durable disease-free survival with a low risk of GVHD in patients with AML. We investigated this approach in 61 patients with primary refractory or relapsed non-Hodgkin lymphoma (NHL), who underwent TCD-HSCT from January 1992 through September 2004. Patients received myeloablative cytoreduction consisting of hyperfractionated total body irradiation, followed by either thiotepa and cyclophosphamide (45 patients) or thiotepa and fludarabine (16 patients). We determined the second-line age-adjusted International Prognostic Index score (sAAIPI) before transplant transplant. Median follow-up of surviving patients is 6 years. The 10-year OS and EFS were 50% and 43%, respectively. The relapse rate at 10 years was 21% in patients with chemosensitive disease and 52% in those with resistant disease at time of HSCT. Nine of the 18 patients who relapsed entered a subsequent CR. OS (P=0.01) correlated with the sAAIPI. The incidence of grades II-IV acute GVHD was 18%. We conclude that allogeneic TCD-HSCT can induce high rates of OS and EFS in advanced NHL with a low incidence of GVHD. Furthermore, the sAAIPI can predict outcomes and may be used to select the most appropriate patients for this type of transplant.Bone marrow transplantation 09/2010; 45(9):1408-16. · 3.00 Impact Factor -
Article: Retroviral Vector‐mediated Gene Transfer and Expression in Nonhuman Primates Following Autologous Bone Marrow Transplantationa
A. GILLIO, C. BORDIGNON, N. KERNAN, P. KANTOFF, M. EGLITIS, J. MCLACHLIN, E. KARSON, S. F. YU, J. ZWIEBEL, A. NIENHUIS, S. KARLSSON, M. BLAESE, D. KOHN, D. ARMENTANO, E. GILBOA, W. F. ANDERSON, R. J. O'REILLYAnnals of the New York Academy of Sciences 12/2006; 511(1):406 - 417. · 3.15 Impact Factor -
SourceAvailable from: bioscience.org
Article: Endocrine complications of pediatric stem cell transplantation.
[show abstract] [hide abstract]
ABSTRACT: Abnormalities of endocrine function and growth are common following stem cell transplantation in the pediatric/adolescent population. Impaired linear growth and adult short stature are associated with younger age at transplant, use of TBI and prior cranial irradiation, and development of chronic GvHD. Primary hypothyroidism is the most common abnormality of the thyroid and is observed in 10-28% of cases following fractionated TBI. Autoimmune hyperthyroidism has also been described post-stem cell transplant and most often results from adoptive transfer of abnormal clones of T or B cells from donor to recipient. Gonadal dysfunction is extremely prevalent and includes oligo-azoospermia in the majority of males treated with TBI, and primary ovarian failure in most women treated with TBI or Busulfan/Cyclophosphamide. Leydig cell function, however, is retained in most males treated with standard forms of cytoreduction. Many patients demonstrate reduced bone mineral density and are at risk of developing osteoporosis in the future.Frontiers in Bioscience 09/2001; 6:G17-22. · 3.52 Impact Factor